INTRODUCTION
Vascular endothelial growth factor (VEGF) is a 34-42 kDa dimeric glycoprotein which is essential for normal kidney development [1] . In adulthood, VEGF is synthesized by visceral glomerular epithelial cells (vGECs) and by very occasional tubular cells. This is well established in vivo in humans at the mRNA and protein levels [2] [3] [4] . The major properties of VEGF are the mediation of increased endothelial permeability (to water and in some circumstances protein) and endothelial mitogenesis (reviewed in [5] ). Although the glomerular filtration barrier is highly permeable to water, VEGF appears to perform neither of these other roles to any great extent in the normal glomerulus -the vast majority of individuals are not nephrotic, and the normal glomerulus is not a site of new vessel formation. The specific role of VEGF in the normal healthy adult glomerulus has therefore been widely debated. Putative roles in the maintenance of the glomerular endothelium (including maintaining fenestration) and permselectivity have been attractive hypotheses [6, 7] .
Differential exon splicing of the VEGF gene results in four main mRNA species which code for four major secreted isoforms : VEGF ")* , VEGF "'& , VEGF "%& and VEGF "#" [5, 8] (the subscript denotes the number of amino acids). Several minor splice variants (VEGF #!'
, VEGF ")$ and VEGF "%)
) have been reported, but their significance remains uncertain [9] [10] [11] . The major isoforms are physico-chemically and functionally distinct. The longer forms in general have a greater ability to bind to heparin and extracellular matrix proteins [5] .
VEGF binds to a number of receptors. These are also functionally distinct. Its major targets are two cell surface tyrosine kinase receptors, VEGFR1 (flt-1) and VEGFR2 (KDR). The latter initiates angiogenesis, cell migration and permeability changes. The role of VEGFR1 is less well defined. Although it can stimulate cellular migration, it has also been implicated as an inhibitor of VEGF activity, by acting as a decoy for VEGFR2 [12] . VEGFR1 also exists in a soluble form (sVEGFR1 ; sFlt) which is inhibitory when bound to free VEGF. These receptors are expressed by the vascular endothelium, including that within the glomeruli [13, 14] . A paracrine action for VEGF has therefore been proposed [13] . These findings would seem to indicate that, for vGEC-secreted VEGF to bind to glomerular VEGF receptors, it would have to move against the gradient of filtration (although this clearly would be down a marked concentration gradient). This apparent paradox has been the subject of much conjecture, since, for some VEGF isoforms at least, movement ' upstream ' would appear difficult -particularly VEGF "#"
, which has no heparin-binding properties and would therefore tend to be washed rapidly into Bowman's space. Furthermore, binding studies also suggest that there are no VEGF receptors in the distal nephron. At first glance, therefore, the production of VEGF "#" by vGECs would seem to be redundant. The neuropilins have recently been identified as potential co-receptors for VEGFR2. They are present in many tissues [15, 16] and appear to be VEGF isoform specific [17, 18] . Neuropilin-1 enhances the binding of VEGF "'& to VEGFR2 [12, 15] , promoting endothelial proliferation and changes in permeability [19] [20] [21] ; indeed, the soluble extracellular neuropilin-1 appears to be sufficient for this augmentation [12] . Furthermore, VEGFR1 may bind to neuropilin-1 to inhibit the above [12] . Neuropilin-1 and neuropilin-2 are receptors for semaphorin class 3 axon guidance receptors (these receptors are involved in directing axonal growth in the developing nervous system). Both receptors also bind VEGF "'& (and placental growth factor). In addition, neuropilin-2 has been shown to bind VEGF "%& [18] , an isoform which, until recently, had only been identified in tissue derived from the female reproductive tract [11] .
The paradoxes described above led us to reconsider the potential expression of VEGF receptors by vGECs. vGECs do not express the tyrosine kinase VEGF receptors [13, 14] . We were therefore prompted to investigate the expression of neuropilin-1, neuropilin-2 and the recently described soluble neuropilin in normal human renal tissue and in cultured vGECs.
METHODS

Nephrectomy tissue
Nephrectomy tissue was supplied by the Department of Urology, Southmead Hospital, from patients undergoing nephrectomy for polar renal tumour (age range 47-78 years). All patients were non-diabetic and normotensive, with normal excretory renal function and no urinary sediment. The research was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association. In line with the local Ethical Committee policy at the time, and previous studies [11] , no formal Ethical Committee approval was required for the study of truly discarded tissue ; however, verbal consent was obtained from the patients. In line with recent guidelines, formal Ethical Committee approval has been granted.
Glomerular harvest and cell culture
vGECs were isolated by sieving, and characterized by immunofluorescence and reverse transcription-PCR (RT-PCR) studies for cytokeratin, WT-1 (Wilm's tumour-1), VEGF, synaptopodin, von Willebrand factor, CD45 and smooth muscle myosin, as detailed previously [22] . Single glomeruli were retrieved as described previously [11] . Pre-prepared adult human kidney library cDNA was obtained commercially from Invitrogen (A550-43).
Molecular studies
Primers
All primer sequences and predicted amplicon lengths are given in Table 1 .
RT-PCR
RNA was extracted from cultured vGECs and whole kidney tissue with guanidinium isothiocyanate following a recognized protocol [23] . cDNA was generated using an RT system kit (Promega, Southampton, U.K.) according to the manufacturer's instructions. Each PCR reaction consisted of 1 µl of 10 µM forward and reverse primer stock (Interactiva), 2.5 µl of 2 mM dNTP, 2.5 µl of 10i buffer (Hybaid), 0.2 µl of gold Taq polymerase (Hybaid) and 100 ng of cDNA, made up to a final volume of 25 µl with nano-pure water.
The general amplification protocol was 94 mC for 5 min (one cycle) ; 94 mC for 20 s, 55-60 mC for 30 s and 72 mC for 30 s (30-35 cycles) ; and finally 72 mC for 5 min (one cycle). The specific number of cycles and annealing temperature for each primer set varied slightly, as determined by preliminary experiments used for optimization. Primer pairs were designed to span different exons to discriminate from genomic DNA. Primer sequences were specific for the target gene. Concurrent RT-PCR studies for VEGF isoforms were undertaken as positive controls. RT-PCR studies of the tyrosine kinase VEGF receptors were also undertaken on cultured podocytes. Positive and negative (no reverse transcriptase) controls were incorporated into each experiment.
Single-glomerular harvest and single-glomerular nested RT-PCR
Single-glomerular harvest and single-glomerular nested RT-PCR were adapted from well established previously published methods [11, 24] . mRNA was extracted from isolated glomeruli using a poly(T) Dynabead kit (Dynal RNA Direct) and following the manufacturer's instructions. Briefly, each glomerulus was lysed and then incubated with poly(T) beads. The beads were washed to remove cell debris prior to a reverse transcription step, which was carried out while the mRNA was still attached to the Dynabeads. Following reverse transcription the cDNA-linked Dynabeads were incubated in 50 µl of TE buffer (10 mM Tris, 1 mM EDTA, pH 8) and heated to 95 mC for 1 min. The cDNA-linked Dynabeads were then resuspended in 50 µl of TE buffer for storage or PCR.
cDNA-linked Dynabeads were washed in 10i PCR buffer (Hybaid Proof 2 buffer) before addition to a 25 µl PCR reaction mixture containing 400 nM each of external forward and reverse primers ( Figure 1 , Table 1 ), 1i Proof 2 buffer (including 2.5 mM MgCl # ) and 200 µM dNTPs (Hybaid). The reaction was ' hot started ' by addition of 0.75 unit of Taq polymerase (PWO proof mix ; Hybaid) in a first-round synthesis as follows : 95 mC for 7 min (Hot start after 3 min), 95 mC for 1 min, 55 mC for 1.5 min and 72 mC for 2 min. The cDNA-linked Dynabeads were then removed by pelleting after 2 min at 95 mC. The supernatant containing the first strand of cDNA was then amplified using 18 cycles of 95 mC for 30 s, 55 mC for 50 s and 72 mC for 50 s, and finished off with a final extension of 5 min at 72 mC.
A 1 µl sample from the first round of PCR was used as template in the second round of amplification. The reaction mixture was as above, except that it contained internal forward and reverse primers for neuropilin-1.
The final MgCl # concentration was 1.5 mM, and 0.75 unit of Taq polymerase was added per reaction. Conditions for the second round were as follows : 95 mC for 30 s, 55 mC for 40 s and 72 mC for 40 s (25 cycles), followed by a 5 min extension at 72 mC. All PCRs were carried out in a Hybaid thermal cycler (Hybaid, Ashford, U.K.). Nested PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was as described previously [11] . Optimal cycle numbers in the first and second rounds of PCR were determined by preliminary experiments. CD45 controls were used to exclude trafficking cells of bone marrow origin in single glomeruli, as described previously [11] .
Detection of PCR products
PCR products were mixed with 3 µl of loading dye (0.25 % Bromophenol Blue\50 % glycerol) and electrophoresed in a 2 % agarose (Sigma) gel. Bands were visualized by ethidium bromide staining on a UVP dualintensity transilluminator.
Protein expression
Western blotting
Podocytes were cultured in a humidified atmosphere of 5% CO # \95 % air at 37 mC for 14 days, and solubilized with RIPA buffer [consisting of 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % Nonidet P-40, 150 mM NaCl, 50 mM Tris and 10 µl\ml proteinase inhibitor cocktail (SigmaAldrich Co.)]. Insoluble material was removed by centrifugation at 12 000 g for 10 min. Soluble material was subjected to SDS\PAGE on an 8 % (w\v) acrylamide gel using reducing conditions, and transferred to a nitrocellulose membrane (Sigma-Aldrich Co.). After blocking with 1 % (w\v) BSA (for immune staining ; SigmaAldrich Co.) plus 1 % (w\v) dried milk (Sigma-Aldrich Co.) and goat IgG, the membrane was incubated with a variety of primary antibodies as for immunohistochemistry detailed below, and then with horseradish peroxidase-conjugated pre-adsorbed secondary antibodies. After the membrane had been incubated in Chemiluminescence Luminol Reagent (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.), X-ray film (Amersham Pharmacia Biotech) was exposed to the membrane, developed and scanned. Subsequently the filter was stripped and re-probed with secondary antibody only.
Immunocytochemistry and immunohistochemistry
Immunocytochemistry was performed on cultured podocytes after incubation and fixation as described previously [22] , using a goat polyclonal anti-neuropilin-1 antibody (Santa Cruz ; sc-7239) diluted 1 : 50 (in Trisbuffered saline) and a secondary FITC-labelled donkey anti-(goat IgG) (Santa Cruz ; sc-2024) diluted 1 : 100 (in Tris-buffered saline). Cells were grown on chamber slides (Lab-Tek II ; Life Technologies, Paisley, Scotland, U.K.). The cells were fixed for 5 min in 1 : 1 (v\v) mixture of ice-cold ethanol (BDH) and acetone (BDH) and blocked in 10 % (v\v) fetal calf serum in PBS, pH 7.4, for 20 min. Appropriate negative controls were used : preincubation of primary antibody with control peptide, isotype control, omission of primary antibody, omission of secondary antibody.
Immunohistochemistry was performed on ' normal ' renal tissue derived from the normal pole of nephrectomy specimens. Tissue was stored frozen and in wax. Since we were unaware of any previously published protocols for the detection of neuropilin-1 protein by immunohistochemistry, a variety of storage, fixation and antigen retrieval methods were used.
Frozen tissue was put directly into liquid nitrogen. Frozen sections were then fixed using a variety of methods, including paraformaldehyde, acetone and alcohol. Wax-embedded tissue was fixed in neutral pH formalin for 4-48 h overnight at room temperature, or microwave-fixed for 20 s. A variety of antigen retrieval methods were used, including trypsin and proteinase K digestion, and pressure cooker\citrate buffer treatment.
Furthermore, each combination of fixation\antigen retrieval for frozen\wax tissue was investigated with all five commercially available anti-neuropilin-1 antibodies of which we are aware. All are polyclonal : (i) rabbit anti-(mouse\rat neuropilin-1) PC343 (Oncogene, Calbiochem, Nottingham, U.K.) ; this antibody was generated using a 14-amino-acid peptide that had one mismatch with the human sequence ; (ii) rabbit anti-(human neuropilin-1) 52-0107 (Zymed, San Francisco, CA, U.S.A.) ; (iii) rabbit anti-(human neuropilin-1) sc-5541 (Santa Cruz) ; (iv) goat anti-(human neuropilin-1) sc-7239 (Santa Cruz), raised against the C-terminus ; and (v) goat anti-(human neuropilin-1) sc-7240 (Santa Cruz), raised against the N-terminus.
Secondary antibodies included : swine anti-rabbit, alkaline phosphatase labelled (Dako DO306) ; donkey antigoat, alkaline phosphatase labelled (Santa Cruz ; sc-2022) ; and swine anti-rabbit, peroxidase labelled (Dako PO217). Alkaline phosphatase was visualized with Nitro Blue Tetrazolium\5-bromo-4-chloro-3-indoyl phosphate as described previously [25] . Immunoperoxidase was detected with a StrAvigen Multilink kit (Biogenex) and visualized with diaminobenzidine chromogen solution (Biogenex).
Negative controls included isotype controls, preincubation with control peptide, omission of primary antibody and omission of secondary antibody. The Zymed control peptide consisted of an 11-amino-acid synthetic peptide derived from the C-terminus of human neuropilin-1. Endogenous tubular alkaline phosphatase was inhibited by pretreatment with 0. 
RESULTS vGEC culture and characterization
Cultured vGECs demonstrated a typical polyhedral shape with a cobblestone appearance on confluence. They were positive for cytokeratin and WT-1 by immunofluoresence. By RT-PCR the cells were positive for VEGF, WT-1 and synaptopodin, and negative for von Willebrand factor, CD45 and smooth muscle myosin, excluding contamination by endothelial cells, leucocytes and mesangial cells respectively. Neuropilin expression by podocytes 
Molecular studies
RT-PCR
Cultured vGECs did not express mRNAs for the tyrosine kinase VEGF receptors (results not shown), although mRNAs for both were present in whole kidney. All renal tissue expressed mRNAs for VEGF
and VEGF "#"
, as described previously [11] . In contrast, PCR products of the predicted size were seen for neuropilin-1, neuropilin-2 and soluble neuropilin in a variety of kidney tissues (Figure 1 ). mRNAs for predicted VEGF isoforms were seen in all kidney tissue examined ( Figure 1 ). Neuropilin-1 mRNA (specific receptor for VEGF "'& ) was seen in total kidney, a soup of sieved glomeruli, cultured vGECs from a number of kidneys and a commercially available kidney library ( Figure 1, lanes 1-5 respectively) . Neuropilin-2 mRNA was seen in cultured vGECs and was only just detectable in total kidney. It was not detected in sieved glomeruli or in the kidney library (Figure 1) . mRNA for soluble neuropilin was demonstrated in cultured vGECs and total kidney, and weakly in sieved glomeruli (Figure 1 ). All these results were reproducible in tissue from four different kidneys.
Nested RT-PCR
Neuropilin-1 products of the predicted size were identified in six of eight single glomeruli isolated within 30 min of nephrectomy ( Figure 2 ). CD45 controls were all negative by nested RT-PCR of single glomeruli (results not shown).
Protein studies
These studies concentrated on the expression of neuropilin-1 protein, because neuropilin-2 mRNA was not seen in any fresh tissue [whole kidney or fresh sieved (non-cultured) glomeruli], and we are unaware of any commercially available antibody that specifically identifies soluble neuropilin.
The best Western blot and immunohistochemistry results were seen with the rabbit anti-(human neuropilin-1) antibody (Zymed ; 52-0107) plus an appropriate secondary antibody. The best immunocytochemistry results were obtained with goat anti-(human neuropilin-1) (Santa-Cruz ; sc-7239) plus appropriate secondary antibody.
Western blotting
A band of the predicted size for neuropilin-1 protein (130 kDa) was detected in primary cultured podocytes ( Figure 3 ). Subsequent stripping of the filter and reprobing with the secondary antibody alone revealed no band.
Immunocytochemistry and immunohistochemistry
Immunocytochemistry revealed intense membrane fluorescence for neuropilin-1 in cultured vGECs ( Figure  4A ). Controls were negative on all occasions (example in Figure 4B ). All antibodies produced a positive signal with wax specimens ; however, the best immunohistochemistry results were seen with the Zymed antibody using 36 h formalin-fixed tissue and pressure cooker\citrate buffer antigen retrieval ( Figure 5 ). All other combinations of fixation, storage, antigen retrieval and antibodies resulted in very faint staining.
Within normal kidney, glomeruli demonstrated varying intensities of staining, with the vGECs showing consistent granular positivity ( Figures 5A, 5C and 5D ). Basement membranes were weakly positive, and in many afferent arterioles and glomerular tufts positivity could be seen in endothelial cells. Mesangial cells demonstrated no convincing staining. Some proximal tubules on some sections demonstrated very weak staining. Not all glomeruli demonstrated staining of equal intensity (Figure 5B) . This mirrors the nested RT-PCR experiment, in which neuropilin-1 mRNA was detected only in some glomeruli. Negative controls gave no signal on any occasion ; an example is shown in Figure 5 (E).
DISCUSSION
This is the first report of the expression of neuropilins in human vGECs. Cultured vGECs synthesize and express neuropilin-1 at the mRNA and protein level in vitro. In addition, neuropilin-1 mRNA is expressed in fresh kidney and in sieved and isolated glomeruli, and neuropilin-1 protein is identified in vGECs in normal human kidney sections.
Although VEGF was initially thought to act on the glomerular endothelial cells within the kidney, recent work has raised the possibility that both mesangial and tubular cells may express VEGF tyrosine kinase or isoform-specific receptors [16, 26] . Thomas et al. [26] have described the expression of VEGFR1 and VEGFR2 in the mesangium of renal biopsies from proliferative renal diseases (in contrast with normal tissue), but neuropilin-1 expression was not investigated. However, all three receptors were present on cultured mesangial cells [26] . A soluble (and truncated) form of neuropilin-1 has been reported to be synthesized by tubular cells, at least at the mRNA level [16] . In mice, in situ hybridization studies for neuropilin-1 have shown a localization of signal to the glomeruli, but further cellular localization was not possible because of relatively poor resolution of isotopic in situ hybridization [25, 27] . Nonisotopic in situ hybridization for soluble neuropilin revealed a tubular signal only [16] . Our immunohistochemistry for neuropilin-1 revealed a signal in the afferent arterioles and glomerular capillaries, with the strongest signal in the vGECs. It is therefore possible that all three major glomerular cell types have the potential to synthesize neuropilin-1.
vGECs have not been shown to express VEGFR1 or VEGFR2. However, the data that we present here highlight the possibility that vGECs may bind VEGF via membrane-bound neuropilin-1.
In situ binding studies have confirmed the presence of VEGF binding sites within the glomerulus ; it has been proposed that these are present principally on the endothelial cells. However, Simon and colleagues [13] were unable to exclude binding of VEGF to vGECs because of the intensity of glomerular staining with exogenous radiolabelled VEGF.
The available data on the expression of VEGF and VEGF receptors on vGECs mirror the findings with a variety of tumour-derived cells (e.g. PC3 prostate carcinoma cells, 231 breast carcinoma cells), which, like vGECs, express VEGF and neuropilin-1, but do not express VEGFR1 or VEGFR2 [15] . In this context it has been proposed that VEGF may have an autocrine role to enhance tumour cell survival, differentiation and motility, or that tumour cell neuropilin-1 may have a VEGF storage or sequestration role [15] . Similar roles clearly should be considered for vGEC-derived VEGF. An autocrine cycle may contribute to vGEC survival or state of differentiation. However, we are not aware of any functional data to support this, and certainly we have been unable to demonstrate VEGF-induced phosphorylation of neuropilin-1 in cultured vGECs, in line with the investigations of Soker and colleagues [15] in tumour cells, although, as these authors note, there are many other potential signalling pathways. We suggest, therefore, that vGEC neuropilin-1 expression may have a simpler role, for example delaying the passage of VEGF into the urinary space by its sequestration on to the podocyte cell surface.
There is increasing evidence that neuropilin-1 can act as a co-receptor for VEGFR2 ; indeed, the presence of neuropilin-1 mediates a 4-fold increase in the binding of VEGF "'& to VEGFR2 [15] . A similar co-receptor role is hypothesized for neuropilin-2 when binding to VEGF "%& . However, there is, as yet, no evidence that the neuropilins can act as functional VEGF receptors in their own right in endothelial cells. Both neuropilin-1 and neuropilin-2 lack cytoplasmic signal transduction domains.
In nervous tissue, neuropilin-1 interacts with a cytoplasmic protein known as neuropilin-interacting protein (NIP), which is identical with two other recently identified proteins, GIPC (GAIP-interacting protein Cterminus) and SEMCAP (M-SEMF cytoplasmic domainassociated protein). This protein is a member of the RGS (regulators of G-protein signalling) family of proteins that act as GTPase-activating proteins [28] [29] [30] . More recently, neuropilin-1 has been shown to form stable complexes with another semaphorin-binding and transducing protein called plexin-1 [31] .
We are unaware of any other tyrosine kinase or Gprotein-linked podocyte receptors that interact with neuropilin-1. The presence or absence in vGECs of intracellular signalling mechanisms similar to those present in neuronal tissue remains speculative, but requires further investigation.
In summary, we submit that vGECs express at least one membrane molecule capable of binding VEGF. Further functional studies are required to address the potential role of vGEC-bound neuropilin-1. 
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